Oculis Holding AG (OCS) Other Non-Current Assets (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Other Non-Current Assets of $1.0 million for Q1 2026, up 79.9% year-over-year from $565023.3 in Q1 2025, and up 3.5% quarter-over-quarter from $982168.3 in Q4 2025.
Oculis Holding AG (OCS) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Oculis Holding AG's Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 79.9% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (up 79.9% YoY), while the FY2025 annual figure was $946810.9, up 74.99% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.0 million, up from $982168.3 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.0 million in Q1 2026, with the low at $76813.6 in Q4 2022.
- The 5-year median for Other Non-Current Assets is $196831.2 (2024), against an average of $411139.4.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets advanced 25.66% in 2024, then surged 466.87% in 2025.
- Oculis Holding AG's Other Non-Current Assets stood at $76813.6 in 2022, then soared by 30.62% to $100334.5 in 2023, then jumped by 441.55% to $543364.4 in 2024, then surged by 80.76% to $982168.3 in 2025, then grew by 3.5% to $1.0 million in 2026.
- Business Quant data shows OCS's Other Non-Current Assets at $1.0 million in Q1 2026, $982168.3 in Q4 2025, and $665058.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 982,168.29 |
| Sep 30, 2025 | 665,058.26 |
| Jun 30, 2025 | 643,805.49 |
| Mar 31, 2025 | 565,023.27 |
| Dec 31, 2024 | 543,364.40 |
| Sep 30, 2024 | 183,518.95 |
| Jun 30, 2024 | 196,831.24 |
| Mar 31, 2024 | 99,674.36 |
| Dec 31, 2023 | 100,334.55 |
| Sep 30, 2023 | 146,047.68 |
| Jun 30, 2023 | 125,675.84 |
| Dec 31, 2022 | 76,813.62 |